Recommendations for Toxicological Evaluation of Nanoparticle Medicinal Products

International Pharmaceutical Product Registration

Volumn , Issue , 2016, Pages 755-761

  Claude, Jean Roger ^a   Domenjoud, L ^a   Fattal, E ^a   Guillemain, J ^a   Guillouzo, A ^a   Le Crom, S ^a   Le Pape, A ^a   Lerondel, S ^a   Lescuyer, P ^a   Morel, F ^a   Pallardy, M ^a   Peltre, G ^a   Pineau, C ^a   Rabilloud, T ^a   Rahmani, R ^a   Tremblay, D ^a   Masset, D ^a   Personne, S ^a  

^a AFSSAPS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85131996999     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420081831-47     Document Type: Chapter

References (5)

1. Opinion on the Appropriateness of the Risk Assessment Methodology in Accordance with the Technical Guidance Documents for New and Existing Substances for Assessing the Risks of Nanomaterials, Scientific Committee on Emerging and Newly-Identified Health Risks, European Commission Health and Consumer Protection Directorate, 21/22 June 2007. http://ec.europa.eu/health/ph risk/committees/04 scenihr/docs/scenihr_o_010.pdf. Accessed November 21, 2008.
2. Organisation for Economic Co-operation and Development Test Guideline 429: Skin Sensitisation: Local Lymph Node Assay (Updated Guideline, adopted April 24, 2002), OECD.
3. Organisation for Economic Co-operation and Development Test Guideline 404: Acute Dermal Irritation/Corrosion (Updated Guideline, adopted April 24, 2002), OECD.
4. Organisation for Economic Co-operation and Development Test Guideline 405: Acute Eye Irritation/Corrosion (Updated Guideline, adopted April 24, 2002).
5. Nanotechnology, A Report of the U.S. Food and Drug Administration Nanotechnology Task Force, July 25, 2007, FDA. http://www.fda.gov/nanotechnology/taskforce/report2007.pdf. Accessed November 21, 2008).